Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2016 | Using ponatinib to treat highly resistant chronic myeloid leukemia, results from a Phase I trial

Michael Mauro • 9 Dec 2016
ASH 2016
Chronic Myeloid Leukemia Ponatinib

Michael J. Mauro, MD from the Memorial Sloan Kettering Cancer Center, New York, NY discusses his highlights from the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA. Dr Mauro describes the latest results from a Phase I trial using ponatinib in chronic myeloid leukemia (CML) patients. Positive results were seen in patients who were given lower doses, which is promising as experts are currently looking at using lower doses of ponatinib moving forward. Dr Mauro believes that toxicity needs to be further monitored when treating with ponatinib but with the correct doses ponatinib is a good drug for highly resistant CML patients. This video has been supported by Incyte through an unrestricted educational grant.

More from Michael Mauro

6:31
An overview of trials investigating asciminib in the treatment of Ph+ CML
Michael Mauro • 18 Dec 2023
2:26
ASCEMBL: asciminib versus bosutinib in third-line treatment of CP-CML
Michael Mauro • 18 Dec 2023
1:14
Unmet needs in pediatric CML
Michael Mauro • 22 Oct 2022
1:52
ESH CML session highlights: pediatrics, biomarkers, and COVID
Michael Mauro • 22 Oct 2022

Related Videos

1:13
The pitfalls in genomics for myeloid malignancies
Thomas Coats • 29 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
2:02
Optimizing myeloablative conditioning with precision-engineered Orca-T in older patients
Caspian Oliai • 10 Dec 2023
3:21
A Phase I trial of Hu8F4, an anti-PR1/HLA-A2 monoclonal antibody, in R/R myeloid malignancies
Tapan Kadia • 14 Dec 2023
The content of VJHemOnc is intended for healthcare professionals